Tax Planning Starts With Knowing Where You Stand

Tax exposure can change a cannabis company’s business-line profitability enough to shift where it makes sense to invest. This article examines how the current tax position provides a basis for evaluating expansion, reallocating capital or reducing an operation. Differences between medical and adult-use taxation, together with the obligations attached to particular products and transactions, help explain how those decisions affect the earnings and cash the business retains.

Expansion into beverages, medical cannabis or hemp-derived products can change both the composition of taxable income and the obligations generated along the supply chain. Even when activities share production space, distribution relationships and administrative staff, differences in deductibility and transaction taxes can produce substantially different returns on the capital employed. Those returns also depend on the consequences for existing operations, including displaced production, additional overhead and the liquidity already committed to tax payments. 

The relevant comparison is therefore between the existing business projected forward under applicable rules and the business after expansion or contraction. This distinguishes the tax benefits attributable to an operating decision from those the company would receive without changing its activities. A historical effective tax rate offers a limited guide when the proposed operation differs in product classification, jurisdiction or eligibility for deductions, as diversification within cannabis and hemp frequently entails.

The tax spread between medical and adult use

Let’s break down the argument we propose from the easiest starting point: rescheduling and its obvious effects on your tax exposure. The April 2026 rescheduling rule moved qualifying state-licensed medical marijuana and FDA-approved marijuana products to Schedule III. Because Section 280E restricts deductions and credits associated with trafficking in Schedule I or II substances, qualifying medical activities gain access to deductions that remain restricted for adult-use operations. The resulting difference can materially alter the revenue required to earn an acceptable return.

In a simplified C-corporation model, $1 million in revenue, $600,000 in properly calculated cost of goods sold and $250,000 in operating expenses produce $150,000 of pretax profit. Assuming those operating expenses are fully disallowed under 280E and fully deductible in the medical case, the 21% federal corporate income-tax rate produces the following results:

The $52,500 difference equals 5.25% of revenue. Federal income tax absorbs 56% of pretax profit in the restricted case, compared with 21% in the medical case. Holding the 60% cost-of-goods-sold ratio and $250,000 operating-cost base constant, the medical operation would match the adult-use operation's $66,000 profit after federal income tax at approximately $834,000 in revenue, about 16.6% less.

This is a modeled comparison excluding state and local taxes, credits, losses, and other adjustments.

The timing also matters: deductions arising during a loss-making launch may have a deferred cash benefit, depending on when and where the resulting losses can be used.

But the benefit also depends on where the company starts. Relief attributable to existing medical operations belongs in the forecast without expansion. Treating it as a return generated by the new investment would inflate the project's contribution. At the state level, New Jersey has allowed qualifying licensees to calculate business income without 280E since tax years beginning in 2023, so federal relief need not produce an equivalent new state benefit.

Mixed operations add an allocation question. Shared labor, occupancy and administrative expenses make the projected benefit sensitive to how those costs are allocated. A consolidated margin alone cannot reveal that exposure. Treasury’s April announcement anticipated guidance on how 280E applies to businesses with multiple activities, for example by apportioning expenses, and on transition-year treatment. As of today, the 2026–2027 Priority Guidance Plan, released in September 2026, lists guidance under Section 280E as a project for the year ending September 2027, without specifying its scope or setting a deadline for completion of the project.

Product mix and the cost of reaching the customer

Income-tax relief operates alongside taxes imposed on transactions and production. For instance, Illinois applies a 20% purchaser excise tax to adult-use cannabis-infused products, including beverages. Non-infused products face 10% at adjusted THC of 35% or less and 25% above that threshold. State and local sales taxes apply separately, while cultivation carries its own 7% tax on taxable receipts from the first sale.

Those levies apply at different stages and to different bases. A frequent mistake is to add up percentages. That will most definitely misstate the burden. For a beverage manufacturer, the retail excise tax enters the investment case through the final consumer price and the margin available across the distribution chain, even when the manufacturer does not remit that tax. A fixed consumer price leaves less revenue for the chain as the tax component rises; passing it through preserves the pretax price but exposes volume to the customer's response.

Medical status produces different combinations elsewhere. California exempts qualifying medical purchases from sales and use tax when the purchaser presents a valid Medical Marijuana Identification Card and government-issued identification, while retaining the 15% retail cannabis excise tax. In New Jersey, the Social Equity Excise Fee is $2.50 per usable ounce on applicable recreational cultivator sales and transfers in 2026, with exclusions including qualifying transfers for medical use. Medical and adult-use production can therefore carry different tax costs before reaching retail.

Vertical integration adds another layer. New Jersey permits municipal transfer taxes of up to 2% for cultivators, manufacturers and retailers, and 1% for wholesalers, with actual rates set locally. Corresponding user-tax provisions can reach transfers between establishments of a concurrent license holder. Bringing a supplier or sales channel inside the group can eliminate an external transaction without necessarily eliminating the local tax event. The consolidated forecast and the tax calculation can therefore recognize the same product movement differently.

Hemp-derived beverages introduce a change within the investment horizon itself. Public Law 119-37 schedules a narrower federal hemp definition for November 12, 2026, including exclusions for finished cannabinoid products exceeding 0.4 milligrams per container of total THC and specified similarly acting cannabinoids. A forecast that extends today's product classification and sales channels across several years may consequently misstate both market access and tax exposure.

Bottom line is… these  rules help illustrate why an existing business's average tax burden cannot reliably price a new activity. The same sales forecast can produce different obligations depending on the product, license, transaction and destination.

The economics of reallocating capacity

The comparison becomes more demanding when expansion displaces an existing activity. A beverage line using idle space may require limited additional fixed investment. The same line occupying productive capacity must earn enough after tax to compensate for the contribution surrendered elsewhere. An attractive standalone margin can coexist with a weak return for the company funding the project.

Contraction creates the reverse problem. A stronger medical return may support reducing adult-use production, but the financial gain depends on the costs that actually disappear. A unit reporting a loss after corporate overhead allocations may still cover part of the rent and shared salaries that continue after closure. Moving those charges to the remaining units changes reported divisional profitability without improving cash generation. Termination costs and inventory dispositions can further delay the benefit.

For that reason, the relevant projection follows the change through the whole business: incremental earnings after tax, displaced contribution, avoidable costs and capital committed during the transition. Separate tax calculations remain necessary for each liable entity, even when management evaluates the combined economic result.

Payment timing can alter which option is feasible. Accrued income taxes, customer taxes awaiting remittance, debt service, and owner tax distributions can absorb liquidity before the new activity generates cash. Equipment and initial inventory add funding requirements that annual profit does not capture. A project with the higher eventual return may require a larger financing commitment or a slower rollout.

This is where ongoing accounting becomes consequential to capital allocation.

Current balances establish the funding constraint; activity-level results support the tax assumptions; subsequent closes show whether the projected contribution is materializing. Verdant's Client Accounting Services and tax advisory support connect that accounting work with projections, giving operators a continuing basis for evaluating what an expansion, reallocation or reduction would add to the business.